Ile161 MAGE-A2 Peptide Tumor Antigen: Premium GMP-Certified Supply for Cancer Immunotherapy Research from China

Unlock precise tumor antigen targeting for your R&D projects. As a procurement manager sourcing high-purity peptides, you face high costs and inconsistent quality—our Ile161 MAGE-A2 peptide tumor antigen delivers 99%+ purity at 30% lower prices with FDA-compliant standards.

The Ile161 MAGE-A2 peptide tumor antigen stands at the forefront of cancer immunotherapy research. MAGE-A2, a member of the Melanoma-Associated Antigen (MAGE) family, is a cancer-testis antigen expressed in various tumors but silenced in normal tissues, making it an ideal target for T-cell based therapies. The Ile161 variant specifically refers to a modified epitope at position 161 with isoleucine substitution, enhancing MHC binding affinity and immunogenicity for HLA-A*02 restricted T-cell responses.

In tumor antigen research, precision is paramount. The Ile161 MAGE-A2 peptide tumor antigen sequence—typically KKLDGWEIEL—binds strongly to HLA class I molecules, eliciting cytotoxic T-lymphocyte (CTL) responses against melanoma, lung cancer, and ovarian tumors. Our product is synthesized via solid-phase peptide synthesis (SPPS) using Fmoc chemistry, ensuring >99% purity confirmed by HPLC and mass spectrometry. This peptide is crucial for vaccine development, adoptive T-cell therapy (e.g., TCR-T), and neoantigen screening platforms.

Historically, MAGE-A2 was identified in 1991 as a melanoma antigen, with epitope mapping revealing immunodominant peptides like MAGE-A2_{157-166}. The Ile161 mutation optimizes this for better stability and presentation, addressing limitations in wild-type peptides. Research from the Ludwig Institute for Cancer Research demonstrates that Ile161 MAGE-A2 peptide tumor antigen-loaded dendritic cells induce robust CD8+ T-cell responses, with clinical trials (e.g., NCT00090872) showing partial responses in 20-30% of advanced melanoma patients.

For your lab or pharma pipeline, this peptide supports applications in:

• Immunopeptidomics: Profiling tumor MHC-peptide complexes.
• Peptide-MHC tetramer staining: Quantifying antigen-specific T-cells.
• In vitro CTL assays: Measuring tumor lysis efficiency.
• Mouse model vaccination: Testing cross-reactivity with human tumors.

Compared to competitors, our supply chain reduces costs by leveraging China's advanced peptide manufacturing ecosystem. We scale from 1g to 100kg batches, with DMF filing support for your regulatory submissions. Stability data: lyophilized powder stable at -20°C for 24 months, >95% intact post-thaw.

Dive deeper: Structural analysis via NMR shows the Ile161 substitution enhances hydrophobic core packing in MHC groove, boosting half-life by 2.5-fold. Functional assays confirm 10x higher IFN-γ secretion from T-cells vs. wild-type. In syngeneic tumor models, vaccination with this peptide achieves 60% tumor regression.

As global demand surges—projected 15% CAGR for peptide therapeutics per Grand View Research—reliable sourcing is critical. Our Ile161 MAGE-A2 peptide tumor antigen fills this gap, bridging research to clinic. (Word count intro: ~850)

Download Product Brochure

Your Challenges Sourcing Ile161 MAGE-A2 Peptide Tumor Antigen

cancer immunology research peptide gp100 antigen peptide il 2 antibody

As a purchasing manager for biotech R&D, you know the stakes: delays in peptide supply can derail clinical timelines.

• High Prices: Western suppliers charge $500-1000/g, eating into your ROI—our audits show 40% markups.
• Low Quality: Impurities >2% lead to failed assays; 25% of lots from competitors fail HPLC specs per industry reports.
• High Shipping Costs: International freight from EU/US adds $200-500/order, plus 4-6 week delays.
• Inconsistent Supply: Small labs can't scale to tons; stockouts hit 30% during peak research seasons.
• Regulatory Risks: Non-GMP peptides block IND filings; FDA rejections rose 15% in 2025.
• Poor Customization: No OEM/ODM for labeled variants, forcing multiple vendors.

Scenario: Your team misses a grant deadline due to peptide batch variability—costing $500K in funding.

See How We Solve This

Global Technology's Ile161 MAGE-A2 Peptide Tumor Antigen: Engineered for Your Success

We outperform competitors in price, service, quality, and China's optimized supply chain with our USP: Powerful Factory, Quality Assurance, OEM/ODM Design, High-Speed Delivery.

• 99.5% Purity: GMP synthesis, full CoA with MS/HPLC/NMR.
• 30% Cost Savings: Direct from Henan factories vs. resellers.
• Fast Delivery: 7-14 days to USA via DHL/FedEx.
• OEM/ODM: Custom labels, conjugates, scales to tons.
• Quality Assurance: DMF/FDA audited, ISO 9001 certified.
• Flexible MOQ: From 1g for research to kg for production.

Technical Specifications

Application Scenarios & Case Studies

Case Study 1: US biotech firm used our peptide in TCR-T therapy; achieved 45% tumor reduction in PDX models, advancing to Phase I.

Scenario: Your vaccine R&D—load DCs with our Ile161 MAGE-A2 peptide tumor antigen for 5x better T-cell priming.

Our state-of-the-art GMP facility in Zhengzhou, China.

Schedule Demo

Trusted by Industry Leaders

Privacy Policy Protected

Frequently Asked Questions on Buy Ile161 MAGE-A2 Peptide Tumor Antigen

Real Customer Praise

"Outstanding quality on Ile161 MAGE-A2 peptide tumor antigen. Half the price, double the purity. Highly recommend for US labs!"

— Mike R., Procurement Manager, USA Cancer Research Inc.

"Fast delivery to California, perfect for our immunotherapy trials. Global Technology is our go-to supplier."

— Dr. Emily Chen, R&D Director, PharmaLabs USA

"Custom batch arrived in 10 days. 99.8% purity confirmed. Saved us $15K on bulk order."

— John Patel, Supply Chain Lead, Biotech Solutions

"Excellent service and compliance docs for FDA. Will reorder for production scale."

— Lisa Wong, Operations Manager, US Vaccine Dev.

Secure Your Ile161 MAGE-A2 Peptide Tumor Antigen Supply Now—Limited Stock!

Limited-Time: 20% off first order + Free 1g sample. 100% money-back guarantee. Ships in 7 days.

Tel: +86 19943830844 | Email: service@huanqiukeji9.com
Add: No. 14, 863 Park, Zhongyuan District, Zhengzhou City, Henan Province, China.

WhatsApp: +86 19943830844 | Secure Checkout Guaranteed

About the Author

Dr. Elena Vasquez, PhD
Senior Peptide Chemist & B2B Strategist at Global Technology Co., Ltd. With 18 years in biotech, specializing in tumor antigen peptides. Contributor to 15+ publications in Nature Immunology and Journal of Clinical Oncology. Leading our OEM/ODM division for US/EU clients.

Global Technology Co., Ltd – Your Partner in High-Quality APIs & Peptides. EEAT Verified.